Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Synta Pharmaceuticals announces pricing of public offering of shares

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $4.50 per share for gross proceeds of approximately $25 million.

8 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

Genzyme enters into mutual cooperation agreement with Relational Investors

Genzyme Corporation and San-Diego based institutional investor Relational Investors LLC announced today that they have entered into a mutual cooperation agreement. Relational, a $6 billion private investment fund, began investing in Genzyme shares in late 2008 and currently owns approximately 4 percent of the company’s common stock.

8 Jan 2010

China Medicine enters into Stock Subscription Agreement with OEP

China Medicine Corporation ("China Medicine" or "the Company"), primarily a leading distributor and a developer of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other nutriceuticals today announced that it has entered into a Stock Subscription Agreement for an equity private placement (the "Subscription Agreement") with One Equity Partners ("OEP"), the global private equity investment arm of JPMorgan Chase & Co.

7 Jan 2010

U.S. Marshals seize all FDA-regulated foods susceptible to contamination by rodents and insects

At the request of the U.S. Food and Drug Administration, U.S. Marshals today seized bulk restaurant food productat Won Feng Trading Company, a food processor and warehouse in Nashville, Tenn. The products are adulterated under the Federal Food, Drug, and Cosmetic Act because they have been held under unsanitary conditions whereby they may have become contaminated with filth.

7 Jan 2010

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with BioPro Pharmaceutical, Inc. (“BioPro”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the “Territories”).

7 Jan 2010

Educational sessions and special workshops highlight advancements in molecular imaging

SNM's Conjoint Mid-Winter Meetings, Jan. 27-Feb. 2, 2010, in Albuquerque, N.M., will bring together four scientific meetings under one umbrella. The meeting, which provides attendees with the opportunity to earn up to 25 continuing education credits, will highlight the latest advancements in molecular imaging and nuclear medicine. The educational sessions will conclude with special workshops on nanomedicine and clinical trials.

7 Jan 2010

Microbia creates carotenoids for food ingredient and nutritional supplement markets

Microbia, Inc., an emerging leader in the production of sustainable specialty ingredients and biomaterials, today announced that it has achieved an important milestone in creating its line of naturally derived carotenoids for the food ingredient and nutritional supplement markets.

7 Jan 2010

Drug companies still under great and growing pressure to bring more products to market

Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success will depend on how well they partner with other firms at specific points on the development spectrum, according to the Tufts Center for the Study of Drug Development.

7 Jan 2010

Scientists use NIR to predict how quickly pills dissolve in body

Scientists at the University of Maryland, Baltimore have successfully used near-infrared spectroscopy (NIR) -- a method already used to test farm product quality -- to predict how quickly pills dissolve in the body.

7 Jan 2010

BC Tech's new, miniature single use video camera can help reduce healthcare costs

BC Tech, a medical product development and manufacturing company, has launched a miniature single use video camera that can be integrated into medical devices to improve safety and help reduce healthcare costs.

7 Jan 2010

DBA Analytical to host a 2-day training course on dietary supplements

DBA Analytical, an NSF International company, which provides a full range of compliance services for FDA regulated industries, will host a 2-day training course on 21 CFR 111, the Current Good Manufacturing Practices (cGMPs) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements.

6 Jan 2010

Pfizer and Strides Arcolab announce new collaboration

Pfizer (NYSE: PFE) and Strides Arcolab today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit.

6 Jan 2010

BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

BioMimetic Therapeutics, Inc. today announced that effective December 31, 2009, the Company amended and restated its manufacturing and supply agreement with Novartis Vaccines and Diagnostics, Inc. for the supply of bulk rhPDGF-BB to BioMimetic.

6 Jan 2010

ORNL story tips for January 2010

World-class computing at Oak Ridge National Laboratory could be unleashed to save as much as $50 billion per year in fraud, waste and abuse in the nation's health care system.

6 Jan 2010

Toxic chemicals make us susceptible to a wide range of diseases

From the Industrial Revolution and onward, the world has become an environment that is overflowing with dangerous toxins. Mass manufacturing has resulted in thousands of chemical pollutants being released in the atmosphere, water, and soil. As well, there has been a widespread increase of chemicals being added to almost every type of food and retail product.

6 Jan 2010

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Agilent Technologies, Inc. (NYSE:A) and Covaris Inc. today announced a co-marketing agreement in which Covaris S2 DNA shearing technology will be marketed with the Agilent SureSelect Target Enrichment System to streamline next-generation sequencing experiments.

6 Jan 2010

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

Manufacturing News and Research

Further Reading

Synta Pharmaceuticals announces pricing of public offering of shares

3Sbio submits registrational clinical trial application for Feraheme injection

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Genzyme enters into mutual cooperation agreement with Relational Investors

China Medicine enters into Stock Subscription Agreement with OEP

U.S. Marshals seize all FDA-regulated foods susceptible to contamination by rodents and insects

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Educational sessions and special workshops highlight advancements in molecular imaging

Microbia creates carotenoids for food ingredient and nutritional supplement markets

Drug companies still under great and growing pressure to bring more products to market

Scientists use NIR to predict how quickly pills dissolve in body

BC Tech's new, miniature single use video camera can help reduce healthcare costs

DBA Analytical to host a 2-day training course on dietary supplements

Pfizer and Strides Arcolab announce new collaboration

BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

ORNL story tips for January 2010

Toxic chemicals make us susceptible to a wide range of diseases

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®